Sophiris Bio, Inc.(Other OTC/NBB : SPHS)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-1.56%||159.39||0.7%||$1248.60m|
|LLY||Eli Lilly & Co.||-2.22%||325.57||1.1%||$1081.56m|
|BMY||Bristol-Myers Squibb Co.||-1.08%||69.49||1.0%||$743.77m|
|MRK||Merck & Co., Inc.||-0.27%||87.20||0.7%||$695.74m|
|ALNY||Alnylam Pharmaceuticals, Inc.||-3.37%||195.56||8.2%||$217.26m|
|HZNP||Horizon Therapeutics Plc||-4.86%||64.59||5.4%||$179.53m|
|GBT||Global Blood Therapeutics, Inc.||0.00%||68.49||5.4%||$178.81m|
|IDXX||IDEXX Laboratories, Inc.||-4.12%||331.76||3.9%||$176.73m|
|SRPT||Sarepta Therapeutics, Inc.||-2.60%||111.83||12.4%||$138.04m|
|AKRO||Akero Therapeutics, Inc.||-2.55%||38.26||0.0%||$130.75m|
Sophiris Bio Inc. (NASDAQ: SPHS) is a biopharmaceutical company developing a clinical-stage, targeted treatment for the symptoms of benign prostatic hyperplasia (BPH or enlarged prostate), which it believes is an unsatisfied patient population with significant market potential. Sophiris is currently developing PRX302 for the treatment of BPH symptoms which is designed to be as efficacious as pharmaceuticals, less invasive than the surgical interventions, and without the sexual side effects seen with existing treatments. PRX302 is currently in Phase 3 clinical development with a blinded interim analysis expected in the second half of 2014 followed by a complete data analysis in the second half of 2015. For more information, please visit www.sophiris.com.